Bourlon R, Gallegos C, Zárate-Osorno A, Carrillo J, Martínez M, Vázquez P, Candelaria M

Idioma: Español
Referencias bibliográficas: 25
Paginas: 67-72
Archivo PDF: 358.15 Kb.

RESUMEN

La enfermedad de Castleman es un padecimiento linfoproliferativo atípico, de evolución variable, con pronóstico grave en ausencia de tratamiento. Las causas de la mortalidad en estos pacientes son: infecciones, insuficiencia renal y neoplasias (incluido el linfoma y el sarcoma de Kaposi). Se describe el caso de un varón de 38 años de edad, con enfermedad de Castleman multicéntrica avanzada, que acudió con síndrome de desgaste y adenomegalia generalizada; recibió tratamiento con quimioterapia y con el anticuerpo monoclonal anti-CD20. El conocimiento y sospecha clínica de esta enfermedad es indispensable para permitir el tratamiento oportuno y evitar las complicaciones.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Castleman B, Towne V. Case records of the Massachusetts General Hospital: Case no 40231. N Engl J Med 1954;250:1001-1005.

2. Bowne J, Lewin JJ, Filippa DA, et al. The Management of Unicentric and Multicentric Castleman’s Disease. A Report of 16 Cases and a Review of the Literature. Cancer 1999;85:706-717.

3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670-683.

4. Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-1216.

5. Roca B. Casleman’s Disease. A Review. AIDS Rev 2009;11:3-7.

6. Casper C. New approacches for the treatment of human herpesvirus 8-associated disease. Rev Med Virol 2008;18:321-329.

7. Candelaria M, Luna-Ochoa E, Labardini-Mendez J, et al. Virus y neoplasias hematológicas. Rev del Instituto Nacional de Cancerología 2009;4:217-235.

8. Dham A, Peterson B. Castleman Disease. Curr Opin Hematol 2007;14:354-359.

9. Cronine D, Warneke WA. Castleman´s Disease. An Update on Classification and the Spectrum of Associated Lesions. Adv Anat Pathol 2009;16:236-246.

10. Stebbing J, Pantanowitz L, Dayyani F, et al. HIV-associated multicentric Castleman’s Disease. Am J Hematol 2008;83:498-503.

11. Mylona E, Baraboutis L, Lekakis L, et al. Multicentric Castleman´s Disease in HIV infection: a systemic review of the literature. AIDS Rev 2008;10:25-35.

12. Kojima M, Nakamura N, Tsukamoto N. Clinical implications of idiopathic multicentric Castleman´s Disease among Japanese: A report of 28 cases. Int J Surg Pathol 2008;16:391-398.

13. Jongsma T, Verburg R, Geelhoed-Duijvestin P. Castleman’s Disease: A rare lymphoproliferative disorder. Eur J Inter Med 2007;18:87-89.

14. González-Guerra E, Harmo MR, Fariña FC, et al. Glomeruloid haemangioma is not always associated with POEMS syndrome. Clin Exp Dermatol 2009;34:800-803.

15. Oksehendler E, Boulanger E, Galicier L. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-2336.

16. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523-531.

17. Coca S, Salas I, Martínez R, et.al. Meningeal Castleman’s Disease with multifocal involvement: a case report and review of the literature. J Neurooncol 2008;88:37-41.

18. Sobrevilla-Calvo P, Avilés-Salas A, Cortés-Padilla D, et al. Características clinicopatológicas de la enfermedad de Castleman´s. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj 2009;77:187-192.

19. Starkey C, Joste N, Lee F. Near total resolution of multicentric Castleman´s Disease by prolonged treatment with thalidomide. Am J Hematol 2006;81:303-304.

20. Gerard L, Berezne A, Galicier L. Prospective study of rituximab in chemotherapy-dependent HIV associated multicentric Castleman’s disease. ANRS 117 Castleman B trial. J Clin Oncol 2007;25:3350-3356.

21. Bower M, Powles T, Williams S. Brief communication: rituximab in HIV-associated multicentric Castleman´s Disease. Ann Intern Med 2007;147:836-839.

22. Stary G, Kohrgruber N, Herneth A, et al. Complete regression of HIV-associated multicentric Castleman´s Disease treated with rituximab and thalidomide. AIDS 2008;22:1232-1234.

23. Fragasso A, Mannarella C, Ciancio A, et.al. Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman´s Disease. Leuk Lymphoma 2008;49:2224-2226.

24. Matsuyama M, Suzuki T, Tsuboi H. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med 2007;46:771-774.

25. Casper C, Krantz E, Corey L. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind placebo controlled, crossover trial. J Infect Dis 2008;198:23-30.